Ali Hassoun, MD
Infectious Disease · Huntsville, ALNPI 1063404978
Payments from drug & device makers
Across 672 payments — averaging $390.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$80K
- Ferring Pharmaceuticals Inc.$67K
- Astellas Pharma US Inc$40K
- Melinta Therapeutics, LLC$30K
- Cumberland Pharmaceuticals, Inc.$14K
- Tetraphase Pharmaceuticals, Inc.$9K
- plus $23K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $80,066 |
| Ferring Pharmaceuticals Inc. | 124 | $67,354 |
| Astellas Pharma US Inc | 86 | $39,626 |
| Melinta Therapeutics, LLC | 66 | $30,221 |
| Cumberland Pharmaceuticals, Inc. | 51 | $13,609 |
| Tetraphase Pharmaceuticals, Inc. | 15 | $8,506 |
| AbbVie(2 entities) | 90 | $6,601 |
| Merck | 43 | $5,414 |
| GSK | 4 | $3,291 |
| Shionogi Inc | 4 | $2,660 |
| La Jolla Pharmaceutical Company | 14 | $2,023 |
| Insmed, Inc. | 54 | $1,034 |
| Gilead | 18 | $396 |
| Viiv Healthcare Company | 20 | $363 |
| Theratechnologies Inc. | 11 | $211 |
| Aimmune Therapeutics, Inc. | 5 | $109 |
| Octapharma USA, Inc. | 1 | $95 |
| Dynavax Technologies Corporation | 5 | $86 |
| Cipla USA Inc. | 1 | $71 |
| Astellas Pharma Global Development | 1 | $64 |
| Janssen Scientific Affairs, LLC | 1 | $62 |
| Grifols USA, LLC | 3 | $62 |
| Mayne Pharma Commercial LLC | 4 | $61 |
| Paratek Pharmaceuticals, Inc. | 2 | $46 |
| Sanofi Pasteur Inc. | 2 | $45 |
| Johnson & Johnson | 2 | $30 |
| AstraZeneca | 1 | $19 |
| Genentech, Inc. | 1 | $17 |
| Advanced Oxygen Therapy Inc. | 1 | $15 |
| T2 Biosystems, Inc. | 1 | $15 |
How this compares
$262,171 in reported general payments places this provider in the 85th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Huntsville
- Ingrid RoigHuntsville$14K
- Scott ParkerHuntsville$11K
- Hafsa SiddiquiHuntsville$5K
- Andres Gutierrez OrdonezHuntsville$2K
- Richard SperaHuntsville$2K
- Jordan Micah PolisticoHuntsville$1K
- Leland AllenBirmingham$8.5M
- Edgar OvertonBirmingham$2.8M
- Peter PappasBirmingham$2M
- John BaddleyBirmingham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.